MJ Lifestyle’s Issue IV: In Her Power Doctors Knox Interview Part I Jalen Reagor Tryout …

⚕️ While media profiles featuring physician advocates for cannabis can raise awareness about cannabinoid research and potential therapeutic applications, clinicians should recognize that promotional or lifestyle content differs substantially from peer-reviewed clinical evidence and may reflect selective reporting rather than balanced risk-benefit assessment. The involvement of medical professionals in cannabis-related business ventures, though not inherently problematic, creates potential conflicts of interest that warrant careful consideration when evaluating claims about therapeutic efficacy or safety. Key confounders include the regulatory status of cannabis products (which often lack FDA oversight), wide variability in cannabinoid composition and labeling accuracy across the market, and the relative scarcity of rigorous clinical trials for most proposed indications beyond a narrow set of approved medications like epidiolex. Healthcare providers should distinguish between emerging preclinical data and established clinical evidence, remain cautious about extrapolating from anecdotal or industry-driven narratives, and counsel patients that most cannabis-based treatments